With a series of clinical trials under its belt already, Medtronic (Minneapolis) continues to lead the way for renal denervation as a means to significantly reduce blood pressure in patients with treatment-resistant hypertension. Last week the company released three-year results from its SYMPLICITY HTN-2 trial at TCT in San Francisco. This week the company followed that up with FDA approval of an investigational device exemption (IDE) for SYMPLICITY HTN-4, the first randomized trial to investigate renal denervation for the treatment of moderate uncontrolled hypertension in U.S. patients.